Upon treatment with barasertib, a known AURKB inhibitor, we observed a significant reduction in BrdU incorporation in fibroblasts isolated from IPF and TGFα model (Fig 4A and B). Here, AURKB is linked to idiopathic pulmonary fibrosis.